TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01710358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Adalimumab placebo administered SC.
Study: NCT00982579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
Study: NCT04394624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
Study: NCT04467957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of CFTR Modulator
Description: Inhaled contrast for MRI occurring at each visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon 129
Description: Inhaled contrast for MRI occurring at each visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon 129
Description: Inhaled contrast for MRI occurring at each visit
Study: NCT02941185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Devit-3 Oral Drop

Intervention type: DRUG
Group type: OTHER
Intervention: Devit-3 Oral Drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Devit-3 Oral Drop
Study: NCT02269436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029 infusion solution
Description: 4 µg/day, continuous i.c.v administration
Study: NCT02479867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: 1 tablet from test vs 1 tablet from reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: 1 tablet from test vs 1 tablet from reference
Study: NCT06017115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Description: Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Description: Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
Study: NCT03341806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MRI-guided LITT therapy
Description: (Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
Study: NCT05143242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hard tissue augmentation at the buccal aspect of single implants.
Description: One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation at the buccal aspect of single implants.
Description: A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
Study: NCT02081391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution 4 mg/mL
Description: Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution 20 mg/mL
Description: Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
Study: NCT04218643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Description: IV inserted via ultrasound guidance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: IV inserted via standard technique
Study: NCT04884984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CLL1 CART
Description: Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
Study: NCT01190670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral and Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral and Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral and Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study: NCT01710358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Adalimumab placebo administered SC.
Study: NCT03358810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PES
Description: The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PES
Description: The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
Study: NCT02394002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT03484039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence
Description: Some subjects will be enrolled in a medication adherence course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seizure Documentation
Description: Some subjects will be enrolled in a seizure documentation course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Improvement
Description: Some subjects will be enrolled in a memory improvement course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: Some subjects will be enrolled in a stress management course.
Study: NCT03332667

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
Study: NCT02394002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT03184428

Intervention type: OTHER
Intervention: Postoperative observation and survey
Description: For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
Study: NCT00560885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure Bipolar System
Description: Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
Study: NCT03332667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide
Description: Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide
Description: Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
Study: NCT03896867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anapod™ Humi-Therm Heated Humidification System Breathing Circuit
Description: For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger™ Warming Blanket
Description: For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue).
Study: NCT04059133

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm
Description: Sham treatment (shock wave probe w/o energy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm
Description: Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
Study: NCT00607646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
Study: NCT02908893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-app and push notification mobile messages
Description: Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-app and push notification mobile messages
Description: Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
Study: NCT01805700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine enhanced energy drink
Description: Comparison of different energy drinks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine enhanced energy drink
Description: Comparison of different energy drinks
Study: NCT01710358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally.
Study: NCT00753350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensate™ anchored gastric device
Description: Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
Study: NCT02004717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a
Study: NCT00924053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001474
Description: Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match EGT0001474
Study: NCT01963260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study: NCT02092857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arachidonic acid (25 mg/100 kcal )

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arachidonic acid (34 mg/100 kcal)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
Study: NCT03853187

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Zr-89 labelled durvalumab PET/CT
Description: Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
Study: NCT00965731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Study: NCT02966860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral solution OC/APAP
Study: NCT03064620

Intervention type: BIOLOGICAL
Intervention: PCV
Description: PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011

Intervention type: BIOLOGICAL
Intervention: PCV
Description: PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
Study: NCT01805700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose drink
Description: Glucose drink (containing 84mg glucose alone)
Study: NCT02284399

Intervention type: OTHER
Intervention: non-invasive prenatal testing
Description: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
Study: NCT04079556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco LHW
Description: Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
Study: NCT02868749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
Study: NCT02719418

Intervention type: DRUG
Intervention: Tinzaparin
Description: 3500 Unit or 4500 Unit subcutaneous once daily
Study: NCT02314208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenbilox

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tahor
Study: NCT03722173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: Tablet